middle.news
Actinogen Completes Enrollment in Pivotal Alzheimer’s Trial, Eyes November 2026 Results
8:54am on Thursday 18th of December, 2025 AEDT
•
Healthcare
Read Story
Actinogen Completes Enrollment in Pivotal Alzheimer’s Trial, Eyes November 2026 Results
8:54am on Thursday 18th of December, 2025 AEDT
Key Points
Full enrollment of 246 participants in XanaMIA Alzheimer’s trial completed
Topline final results scheduled for November 2026
Interim safety and futility analysis by independent committee due January 2026
Open-label extension phase to start in Q1 2026 offering active treatment to all participants
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE